



## TheraCryf plc

("TheraCryf", the "Company" or the "Group")

### Marking Addiction Awareness Week 2025

**Alderley Park, 26 November 2025** - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, is supporting Addiction Awareness Week.

23-30 November is the UK's national Addiction Awareness Week 2025, aiming to raise awareness of the challenges and stigma around addiction.

Addictions, particularly Substance Use Disorders, are a chronic, relapsing group of disorders with a high unmet medical need. The number of people affected is astonishing, with up to 2.2% of the global population estimated to have a Substance Use Disorder<sup>[1]</sup>. Current treatments often see high relapse rates, and there are limited long-term pharmacological options.

Last year in the UK, addiction was the cause of more deaths than road traffic collisions, and it costs the economy more than £21bn per year. Alcohol addiction alone costs the NHS more than £3.5bn per year.

TheraCryf is honoured to be contributing to the potential treatment of addiction with its lead Ox-1 orexin -1 blocker programme, targeting binge eating disorder and other substance use disorders.

As noted earlier this month, the programme is progressing on budget and ahead of schedule, with the 0.5kg scale-up completed ahead of schedule, manufacturing of 2kg human grade material initiated and the scale-up to 10kg manufacturing proceeding to plan. This is with our aim of achieving clinic readiness by the end of 2026.

TheraCryf has also has robust patent protection for Ox-1, with the recent patent grant in Korea, complementing long lasting patent protection in all major territories including Europe and USA.

**Dr Huw Jones, CEO of TheraCryf, said:**

*"In marking Addiction Awareness Week, we are conscious of the very real unmet medical need in addiction. Addictive disorders affecting hundreds of millions of people and their families across the world, with the global cost burden running into many tens of billions. We are focused on helping to reduce both the human and financial costs of these conditions and getting our promising Ox-1 programme into the clinic as soon as possible."*

-Ends-

#### Enquiries

##### TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

**+44 (0)1625 315 090**

[enquiries@theracryf.com](mailto:enquiries@theracryf.com)

##### Singer Capital Markets (NOMAD & Joint Broker)

Phil Davies / Oliver Platts / Patrick Weaver

**+44 (0)20 7496 3000**

##### Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

**+44 (0)20 3657 0050**

##### Vigo Consulting

Rozi Morris/ Melanie Toyne Sewell

**+44 (0)20 7390 0230**

[theracryf@vigoconsulting.com](mailto:theracryf@vigoconsulting.com)

#### About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma\* and neurodevelopmental disorders (\*orphan indication).

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know-how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM

---

[1] - Castaldelli-Maia, JM et al (2022), 'Analysis of global prevalence of mental and substance use disorders within countries: focus on sociodemographic characteristics and income levels', International Review of Psychiatry, Feb;34(1): pp6-15

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRALELLLEFLBFBX